Turkish Journal of Medical Sciences
Volume 51

Number 1

Article 1

1-1-2021

Perspectives for immune plasma treatment of COVID-19
BAŞAK SAYINALP
OLGU ERKİN ÇINAR
İBRAHİM CELALETTİN HAZNEDAROĞLU

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
SAYINALP, BAŞAK; ÇINAR, OLGU ERKİN; and HAZNEDAROĞLU, İBRAHİM CELALETTİN (2021)
"Perspectives for immune plasma treatment of COVID-19," Turkish Journal of Medical Sciences: Vol. 51:
No. 1, Article 1. https://doi.org/10.3906/sag-2005-410
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss1/1

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences
http://journals.tubitak.gov.tr/medical/

Review Article

Turk J Med Sci
(2021) 51: 1-9
© TÜBİTAK
doi:10.3906/sag-2005-410

Perspectives for immune plasma treatment of COVID-19
1

2,

2

Başak SAYINALP , Olgu Erkin ÇINAR *, İbrahim Celalettin HAZNEDAROĞLU 
Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2
Department of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

1

Received: 31.05.2020

Accepted/Published Online: 27.07.2020

Final Version: 26.02.2021

Background/aim: The SARS-CoV-2 infection was declared as a pandemic by the World Health Organization (WHO) on
March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already surpassed
that of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still
no definitive treatment or vaccine. This study aims to explain the background of convalescent plasma (CP) treatment and
its relations with COVID-19 immunity, to define ideal treatment procedures, and to reveal present and future perspectives
in the light of the rapidly growing data.
Immunological basis of COVID-19-associated immune response and convalescent plasma as a treatment option:
Since it has been shown that the impaired immune response of the host is one of the most important factors that increase
the severity of the infection, treatment strategies to suppress aberrant immune activation are currently being considered.
CP, which is derived from recently recovered patients and contains neutralizing antibodies and many other immunemodulatory substances, seems to be the most convenient strategy to restore normal immune function considering the fast
spreading nature of the ongoing pandemic.
Conclusion: Even though mechanisms of action of plasma therapy are not fully delineated, it was shown that it could lead
to a reduction in mortality since other alternatives such as monoclonal antibodies or SARS-CoV-2 hyperimmunoglobulin
require much more time and effort to be developed.
Key words: COVID-19, pandemic, convalescent plasma
1. Introduction
The term ‘epidemic’ comes from the conjugation of the
Greek words ‘epi’ (on) and ‘demos’ (people) and was first
mentioned by Homer. Hippocrates first used this term in
the field of medicine to describe an assortment of clinical
syndromes occurring and spreading at a certain location in
a given period [1]. Over time, the term has been utilized to
describe outbreaks of single infectious diseases, such as the
Bubonic Plague (Black Death), which caused the deaths of
approximately 200 million people between 1347 and 13511.
On March 11th of 2020, the World Health Organization
(WHO) declared that the viral infection and subsequent
outbreak ofSARS-CoV-2 constituted a pandemic2.
‘Pandemic’ is the term used for epidemicscharacterized

by multiple, infectious casesin distinct countries and
continents. COVID-19 and the associated immune
syndrome is a multisystemic disorder following the
development of the SARS-CoV-2 infection. Currently, the
death toll of COVID-19 has already surpassed those of
previous epidemics such as SARS-CoV-1, MERS, Ebola,
Yellow Fever, and the H1N1 influenza virus and mortality
numbers are still growing1.
A wide variety of treatment options are currently being
considered for the challenging COVID-19-associated
immune syndrome. From an immune-biological point
of view, the impaired/deficient immune reaction of the
host could play a prominent role, particularly in patients
presenting with more severe clinical diseases. Drugs and
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treatment options focusing on immune modulation of
the host are currently under development. Convalescent/
immune plasma (CP) derived from recently recovered
patients is a classical way of passive immunotherapy
experienced within the last 80–100 years [2]. Since the
SARS-CoV-2 specific hyperimmune immunoglobulin
preparation or unique monoclonal antibodies require much
more time and effort to be developed, CP, which contains
neutralizing antibodies to the relevant pathogen [3], is the
most convenient way, considering the fast spreading nature
of the ongoing COVID-19 pandemic until an effective
vaccine becomes available.
2. Immunological basis of COVID-19 associated
immune response
Currently, available data indicates that about 80% of SARSCoV-2 infections are asymptomatic or mildly symptomatic,
whereas the remaining 20% can manifest itself as the severe
disease form. The host immune system, together with the
pathogen virus dose, viral strain, time-dependent viral
transmission, and host exposure kinetics determine the
severity of the disease. Since it is a newly emerging disease,
precise data regarding the immunological aspects of the
COVID-19 syndrome are still being collected. The most
analogical explanations are being made based on previous
members of the coronavirus family viruses, namely SARSCoV and Milddle East respiratory syndrome (MERS).[4].
Innate immune system and type-1 interferon molecular
expressions, along with other proinflammatory cytokines,
including IL-1, IL-6, and TNF-alpha, play a central
role in the clearance of coronaviruses [5]. The severe
disease forms of SARS-CoV, MERS, and SARS-CoV-2
are associated with immune evasion strategies. These
biological events enable the viruses to proliferate in the
infected host cells. Eventually, the infected cells undergo
programmed cellular death. Meanwhile, the viral particles,
along with the intracellular components, such as nuclear
antigens triggering the innate inflammatory mechanisms,
are released into the microenvironment. At this critical
biological stage, adaptive immunity with CD4+, CD8+
T-cells, and antibody-producing B-cells is involved, and a
second wave of inflammation takes place [4]. Coronaviruses
could also further lead to lymphocyte apoptosis, another
well-known strategy for immune evasion [6].
In a subpopulation of infected patients with SARSCoV-2, enhanced immune activation could lead to a
cytokine storm, which clearly contributes to disease severity
with increased morbidity and even mortality [7]. The
reduction in the total number of T-cells was demonstrated
in patients with severe COVID-19-associated immune
syndrome requiring intensive critical care. T-cell numbers
are negatively correlated with the circulating IL-6, IL-10, and
TNF-alpha. Patients with a history of recovering fromthe
COVID-19 syndromeshowed a reduced concentration in
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proinflammatory cytokine levels together with increments
in the circulating T-lymphocyte counts. Moreover,
significant increases in exhaustion markers such as PD-1
were observed on the T-cells, which became more apparent
during the clinicobiological course of the COVID-19
associated immune syndrome [8]. Many systems in the
body are affected by the direct cytopathic effect of the virus
or one/several of these immune mechanisms. Some of the
clinical and pathological manifestations are demonstrated
in Figure 1. Although there is much to still learn about
the immune pathology of this newly emerging syndrome,
the impaired and exaggerated immune response seems to
be the most important mechanism that increases clinical
severity. Therefore, treatment strategies to suppress aberrant
immune activation and restore the normal function of the
immune system are urgently needed.
3. Convalescent/immune plasma therapy as a treatment
option
3.1. The concept of passive immune transfer
Passive immunotherapy dates back to the late 19th century,
when patients with diphtheria were treated with the immune
sera of animals such as sheep, goats, or horses. However,
the use of human CP has been in practice since the early
20th century with the emergence of viral outbreaks such as
the 1918 H1N1 influenza virus pandemic [9]. The immune
plasma transfer approach was also used successfully during
the 2003 SARS-CoV epidemic [10], the 2009–2010 H1N1
influenza virus pandemic [11], the 2012 MERS epidemic
[12], and the 2014 West African Ebola epidemic [13]. In a
systematic review and exploratory metaanalysis by MairJenkins et al., the administration ofCP for the treatment
of severe acute respiratory infections of viral etiology was
assessed. The authors concluded that, in spite of the lack
of randomized controlled clinical trials, plasma treatment
could lead to a reduction in mortality, especially when it
is administered in early periods following the onset of the
infection [14]. This observation can be partly explained
by the smaller amount of initial inoculum. Since the viral
load in the initial inoculum is much lower than that of
the established infection, it makes it easier for the passive
antibodies to neutralize them. Viral neutralization and
relevant cellular immunological mechanisms can operate
more efficiently at the beginning of the immune response
[15].
3.2. Mechanisms of action
Several mechanisms are now being proposed for the
mechanism of action ofCP therapy. Neutralizing antibodies,
which bind to the virus and block viral entry, fusion, and
egress, are the most recognized mechanism [16]. A dose
of neutralizing antibodies is correlated with higher viral
load reduction and lower mortality, as suggested in
previous studies on the Ebola virus and the Junin virus, the
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Figure 1. AlthoughCOVID-19 appears primarily as a respiratory disease, many
organs/systems are affected due to the direct cytopathic effect of the virus or
because of the uncontrolled immune response against it.

causative agent of Argentine hemorrhagic fever [17, 18].
The fact that it contains antibodies that neutralize the virus
and block its entrance to host cells by binding to crucial
viral antigens is not the only mechanism of action ofCP.
Immune plasma therapy may also function via modifying
the host inflammatory response and related endogenous
substances.
The efficacy of CP is dependent upon distinct
immunobiological actions [19]. Numerous cellular
responses are involved in the immunological responses,
including T-cells, B-cells, dendritic cells, and macrophages.
They are all involved in the ‘cellular immunity effects’ of
CP via modulation of cytokines and chemokines within
the maturation and activation of each unique cell type.
Although these mediators and their clinical effects have
not yet been exactly ascribed to direct CP contents and in
vivo effects, many postulations have been made regarding
the already known mechanisms of IVIg treatment, which
acts through similar pathways. Antibody-dependent
cellular cytotoxicity, opsonization, and complement
activation take part in humoral immunity. These
complicated biological processes could aid antibodies
in stimulating cellular immunity within the actions of

cytokine/chemokine networks [20]. Passive antibody
administration failed to protect mice deficient in CD4+
T cells, and Th1- and Th2-associated cytokines from
infection [21,22]. Likewise, FrCasE retrovirus-infected
mice to which the passive antibody was administered had
protective immunity in spite of a lower viral inoculum
mimicking the neutralizing function of the antibody [23].
Those in vivo observations generated the hypothesis that
passive antibody administration could lead to similar
immunobiological effects in humans. That hypothesis
will be tested while performing future research during the
ongoing COVID-19 pandemic because, at present, there is
no available and effective vaccine or antiviral drug.
Another important problem in the course of
COVID-19 is coagulopathy, which often occurs in findings
similar to disseminated intravascular coagulopathy or
antiphospholipid antibody syndrome. Critically ill patients
exhibited positivity for anticardiolipin IgA antibodies,
aswell as for anti-β2-glycoprotein I IgA and IgG antibodies
[24].CP therapy may also have a role in terms of blocking
responsible antibody for prevention or amelioration of
antiphospholipid antibody syndrome-like coagulopathy,
just as this has been observed in IVIg therapy.
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3.3. Clinical indications of the immune plasma therapy
The efficacy of CP therapy has not yet been proven by
randomized controlled clinical trials. According to
preliminary data, the most beneficial way to use immune
plasma therapy is within the first 10 days of the disease
course and in COVID-19 patients following severe or lifethreatening disease criteria3.
Severe disease criteria:
- Dyspnea
- Respiratory rate ≥30/min
- Arterial oxygen saturation ≤93%
- Pa/FiO2 ≤ 300
- >50% progression of lung infiltrates within 24–48 h
Life-threatening disease criteria:
- Respiratory failure
- Sepsis or septic shock
- Multiorgan dysfunction or failure
Informed consent must be obtained from the patient
or from the patient’s relatives.
3.4. Donor eligibility
Individuals who donate immune plasma must first be in
good health; meeting universal blood donation criteria
and adhering to standard operating procedures prior to
the pandemic are also important. As with many other
blood product donations, screening should be done for
the main viral infection factors that can be transmitted by
blood. The main essentials of those tests include HIV 1-2
and HIV NAT, anti-HCV-HCV NAT, HBs Ag, and VDRL
but should also include regional infectious diseases, if any.
Special warnings regarding blood donation during the
pandemic period have been specifically stated by WHO4.
The following criteria regarding COVID-19 disease
must be met5:
- During the disease period, a diagnostic test must be
positive (e.g., SARS-CoV-2 PCR with a nasopharyngeal
swab) or a SARS-CoV-2 serological antibody test must be
found to be positive after recovery.
- Complete COVID-19 symptoms have to be resolved
at least 14 days before donation (there is no need to prove
that the PCR test has become negative)
- Donation must be from male donors or nonpregnant
female donors or anti-HLA antibody negativity in women
with a history of pregnancy
- Testing of anti-SARS-CoV-2 antibody titers, if
available:
- Ideally, antibody positivity should be found at a titer
of 1:160 or higher according to the FDA and 1:320 or

higher according to European Commission on Health and
Food Safety. If no alternative is available, a lower titer may
also be effective.
- If the test is not available, it is recommended that the
plasma sample be stored for testing later when available.
It is essential that all these processes be carried out in
authorized and high standard blood banks. The schematic
steps of CP treatment are demonstrated in Figure 2.
3.5. Pathogen reduction
Although it is not yet clear whether the SARS-CoV-2 virus
is transmitted by blood and since plasma products should
not contain any nucleic acid-containing cells (leukocytes
or microorganisms), inactivation of possible pathogens
(especially for those not covered or detected in screening
tests) should be performed in each donated plasma
product in centers with the technical abilities and trained
personnel. For this, solvent/detergent-based treatments
that are very effective against viruses with lipid envelopes
or light-based methods targeting the nucleic acid structure
(e.g., amotosalen + UV, riboflavin + UV, or methylene blue
+ visible light) can be used. Pathogen-reduced plasma
products have not been observed to cause any toxic or
immunologic adverse reactions beyond what would be
expected from any other plasma products.
3.6. Labeling
It is recommended to label the donor’s ABO and Rh groups,
the date of donation, the amount of plasma contained, and
the antibody test result for the patient it is prepared for
[25].
4. Typical clinical application of immune plasma
therapy for the management of COVID-19 in a critical
case
A 55-year-old male with a history of myelodysplatic
syndrome (MDS) with fluorescent antibody test (FAB)
refractory anemia excess blasts-1 subtype (MDS/ RAEB1), complicated by disseminated systemic tuberculosis
and associated kidney disease, was admitted to our
hospital with complaints about an ongoing, high fever and
persistent cough lasting for about 3 days. He had recently
been discharged from the hospital after a follow-up of 2
months for the disseminated tuberculosis infection and
was still on the classic four-drug regimen (isoniazid,
rifampin, pyrazinamide, and ethambutol). Low-dose chest
computed tomography indicated COVID-19 pneumonia
(Figure 3.), and the nasopharyngeal swab sample was also
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Website https://www.fda.gov/media/136798/download [accessed 00 Month Year].
3

World Health Organization (2021). WHO Blood Regulators Network (BRN) Donor Selection in case of Pandemic Situations [online]. Website https://
www.who.int/bloodproducts/brn/DonorSelectionincaseofPandemicSituations.pdf?ua=1 [accessed 20 June 2020].
4

European Commission Directorate-General for Health and Food Safety (2020). An EU Programme of COVID-19 Convalescent Plasma Collection and
Transfusion [online]. Website https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf [accessed 20
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Figure 2. Schematic steps of convalescent plasma treatment.

Figure 3. Typical chest computed tomography findings of a patient with COVID-19 pneumonia shows scattered ground glass densities,
especially involving subpleural and peripheral regions of the lungs.
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Table. Ongoing studies on immune plasma (CP: convalescent plasma) are listed by their key features. Among the studies registered on
the ClinicalTrials.gov database, studies involving 100 or more patients were included. (CP: convalescent plasma, FMTVDM: Fleming
method for tissue and vascular differentiation and metabolism; HCQ: hydroxychloroquine; ICU: intensive care unit; P: plasma; RL:
Ringer’s lactate; SC: supportive care; WHO: World Health Organization).
Title

Country

Efficacy and safety
of novel treatment
Denmark
options for adults with
COVID-19 pneumonia

Phase Design

3

Major outcome measures

CP vs. Sarilumab vs.
All-cause mortality or need
injective placebo,
of invasive mechanical
HCQ vs. Baricitinib
ventilation
vs. oral placebo (all
with SC)

Number of Estimated
cases
completion date

1500

June 2021

CP vs. random P

Cumulative incidence of
hospitalization or death prior
to hospitalization, treatment1344
related serious adverse events
and treatment-related grade 3
or higher adverse events

January 2023

3

CP vs. SC

Intubation or death in
hospital

1200

December 2020

3

CP vs. placebo

COVID ordinal outcomes
acale by day 15

500

April 2021

Convalescent plasma
vs. standard plasma for USA
COVID-19

1–2

CP vs. random P

28 day ventilator free days

500

August 2021

The Fleming
[FMTVDM] directed
CoVid-19 treatment
protocol

2–3

CP and 10 more
treatment options

Improvement in FMTVDM
measurement with nuclear
imaging

500

November 2020

CP vs. SC

Overall mortality until
discharge from the hospital
or a maximum of 60 days
after admission whichever
comes first

426

July 2020

2

CP vs. RL of saline

Percentage of subjects
reporting each severity rating
300
on WHO ordinal scale for
clinical improvement

April 2023

convalescent plasma
therapy vs. SOC for the
Spain
treatment of COVID19
in hospitalized patients

2

CP vs. SC

Category changes in ordinal
scale for hospitalization,
mechanical ventilation etc.

278

July 2020

Convalescent plasma vs.
placebo in emergency
USA
room patients With
COVID-19

2

CP vs. random P

Time to disease progression

206

December 2022

Convalescent plasma
to limit SARSCoV-2 associated
complications

USA

2

Convalescent plasma
for hospitalized adults
with COVID-19
respiratory illness
(CONCOR-1)

Canada

Passive immunity
trial of nashville II for
COVID-19

USA

USA

Convalescent plasma
as therapy for covid-19
severe SARS-CoV-2
Netherlands 2–3
disease (CONCOVID
study)
Convalescent plasma
to limit COVID-19
complications in
hospitalized patients
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Table. (Continued).
Evaluation of SARSCoV-2 (COVID-19)
antibody-containing
plasma therapy

USA

3

CP vs. random P

Modified WHO ordinal scale
220
(MOS) score: day 14

December 2021

Convalescent plasma
collection and
USA
treatment in pediatrics
and adults

3

SC vs. 1 U CP vs. 2
U CP (according to
disease severity)

Survival, morbidity
reduction, length of stay in
hospital

240

March 2021

CP vs. SC

Survival without needs of
ventilator utilization or
use of immunomodulatory
drugs,WHO progression
scale ≥6

120

June 2020

May 2021

182

June 2021

Efficacy of
convalescentplasma
to treat COVID-19
France
patients, a nested trial
in the CORIMUNO-19
cohort

2

A phase II, open
label, randomized
controlled trial to
assess the safety and
India
efficacy of convalescent
plasma to limit
COVID-19 associated
complications

2

CP vs. SC

Composite measure of the
avoidance of - 1. Progression
to severe ARDS (P/F ratio
100
100) and 2. All-cause
mortality at 28 days

Early transfusion of
convalescent plasma
in elderly COVID-19
patients. to prevent
disease progression.

2–3

CP vs. SC

Rate of COVID-19
progression

A study evaluating the
efficacy and safety of
high-T
titer anti-SARS-CoV-2 USA
Plasma in hospitalized
patients with
COVID-19 infection

2

CP in ICU vs. CP in Overall mortality within 60
non-ICU
days, length of ICU stay

131

May 2023

Efficacy of human
coronavirusimmune
convalescent plasma
for the treatment of
COVID-19 disease in
hospitalized children

2

CP vs. SC

Clinical recovery in 30 days

100

May 2022

Plasma therapy of
COVID-19 in Critically USA
ill patients

2

CP vs. random P

Time to improvement

105

April 2021

Efficacy and safety
human coronavirus
immune plasma (HCIP)
vs. control (SARSUSA
CoV-2 nonimmune
plasma) among adults
exposed to COVID-19

2

CP vs. random P

Cumulative incidence of
composite outcome of disease 150
severity

Italy

Canada

January 2023

7

SAYINALP et al. / Turk J Med Sci
found to be positive for the COVID-19 infection; he was
then urgently hospitalized. Taking into consideration the
immunocompromised status of the multimorbid patient
and his worsening status, despite antiviral (favipiravir)
treatment and supportive care, 200 mL of CP was transfused
twice at 2-day intervals. In addition, to break the severe
macrophage activation syndrome-like immune response,
tocilizumab was administered with the 2nd infusion.
In the following period, the patient rapidly improved in
terms of clinical and laboratory values. Timely infusion
of CP in this patient, who had difficult comorbidities and
immune compromisation and an uncontrolled immune
response similar to macrophage activation syndrome, is a
demonstrative example [26].
5. Conclusion
In many countries, large-scale CP studies have started to be
carried out, some of which have involved more than 1500
patients6. In those studies comparing various comparators
with immune plasma, many parameters, especially
effectiveness and safety, were evaluated in terms of a wide
range of clinical outcomes. Studies involving more than
100 patients are summarized in the Table. The results of
those studies show the use of immune plasma and with
which indications and timing it will be most beneficial.
However, some of the most important publications on
immune plasma effectiveness [27] and safety [28] are
already at the preprint stage. The safety data in one study,
which involved 5000 patients, indicated that immune
plasma administration could be considered safe in those
6

with severe or life-threatening diseases. In another study,
in which both efficacy and safety were addressed, immune
plasma treatment was evaluated as safe, and clinical
improvement was achieved in 19 of 25 patients [27].
No significant adverse effect was observed in a study in
which 26 patients were included in a center where the CP
treatment was first applied in a country outside of China.
Six of 17 patients who needed mechanical ventilation
died, while none of the 9 patients who did not require
mechanical ventilation died [29]. As more data from more
studies accumulate, more robust conclusions will be drawn
regarding immune plasma efficacy and safety.
In the near future, antibody-based treatments will
not only constitute CP7. Plans are in motion to purify
polyclonal antibodies such as hyperimmune globulin (HIg) from pooled plasma of donors to develop an unbranded
standard antibody product. With the production of
hyperimmune globulins, an antibody-based treatment will
not have to be stored locally but can be shipped to many
locations worldwide. These types of treatment will also offer
a standardized and highly efficient, scalable option, and
clinical outcomes can be tracked more objectively. If the
expected success is achieved in the previous experiences,
then steps towards the production of recombinant
antibodies in mammalian cell lines can be envisaged.
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